More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

Key Australian Patent for Recces Broad-Spectrum Antibiotics

Jul 31, 2018 at 2:58 AM EDT · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Jul 31, 2018 at 2:58 AM EDT

On 6ix: 6ix.com/news/key-australian-patent-for-recces-broad-spectrum-antibiotics

Recce Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Recce Pharmaceuticals Ltd. on 6ix

Earlier from Recce Pharmaceuticals

  • Update on Progress of Broad Spectrum Antibiotic RECCE 327Jul 18, 2018
  • Update on meeting with US FDAJun 5, 2018
  • Additional AU$861,590 R&D Tax Incentive Rebate ReceivedApr 22, 2018
  • Recce Half Yearly Report and Appendix 4DFeb 28, 2018
  • Data Submission & Further Communication Request with US FDAFeb 14, 2018

Later from Recce Pharmaceuticals

  • Change of Registry Address: Automic P/L - Sydney OfficeSep 28, 2018
  • Recce Successfully Raises $1.8 million via PlacementFeb 7, 2019
  • USA Patent Granted for Recces AntibioticsMar 13, 2019
  • Appointment of Independent Chair and Additional DirectorJul 9, 2019
  • Appendix 4C and commentaryJul 30, 2019
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer